Clinical Benefit, Price, and Regulatory Approval of Cancer Drugs Granted Breakthrough Therapy Designation in China, 2020-2024

The China National Drug Administration (NMPA) established the breakthrough therapy designation (BTD) in 2020 to encourage the accelerated development of drugs for the prevention and treatment of diseases that are life-threatening. However, the differences between BTD and non-BTD cancer drugs regardi...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	JAMA network open 2024-10, Vol.7 (10), p.e2439080
Hauptverfasser:	Luo, Xingxian, Du, Xin, Lv, Xufeng, Yang, Yue, Zhang, Xiaohong, Huang, Lin
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - economics Antineoplastic Agents - therapeutic use Cancer therapies China Cross-Sectional Studies Drug Approval Drug Costs - statistics & numerical data Drugs Health Policy Humans Neoplasms - drug therapy Online Only Original Investigation Prices Regulatory approval
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!